Total-body examination vs lesion-directed skin cancer screening

JAMA Dermatology

Volumn 152, Issue 1, 2016, Pages 27-34

  Hoorens, Isabelle ^a   Vossaert, Katrien ^b   Pil, Lore ^c   Boone, Barbara ^a   De Schepper, Sofie ^a   Ongenae, Katia ^a   Annemans, Lieven ^c   Chevolet, Ines ^a   Brochez, Lieve ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b Private Practice ^*  (Belgium)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANXIETY; ARTICLE; BASAL CELL CARCINOMA; BELGIUM; BOWEN DISEASE; CANCER SCREENING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; HEALTH CARE COST; HISTOLOGY; HUMAN; INCREMENTAL COST EFFECTIVENESS RATIO; INTERMETHOD COMPARISON; LESION DIRECTED SCREENING; MALE; MELANOMA; POPULATION RESEARCH; PREDICTIVE VALUE; PRIORITY JOURNAL; SKIN CANCER; SKIN CARCINOMA; TOTAL BODY EXAMINATION; VISUAL ANALOG SCALE; AGED; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; EARLY CANCER DIAGNOSIS; ECONOMICS; MASS SCREENING; MIDDLE AGED; PATHOLOGY; PHYSICAL EXAMINATION; PROCEDURES; SKIN NEOPLASMS;

ADULT; AGED; BELGIUM; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; MASS SCREENING; MELANOMA; MIDDLE AGED; PHYSICAL EXAMINATION; PREDICTIVE VALUE OF TESTS; SKIN NEOPLASMS;

EID: 84955255839     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2015.2680     Document Type: Article

References (36)

1. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166 (5):1069-1080.
2. de Vries E, van de Poll-Franse LV, Louwman WJ, de Gruijl FR, Coebergh JW. Predictions of skin cancer incidence in the Netherlands up to 2015. Br J Dermatol. 2005;152(3):481-488.
3. Flohil SC, de Vries E, Neumann HA, Coebergh JW, Nijsten T. Incidence, prevalence and future trends of primary basal cell carcinoma in the Netherlands. Acta Derm Venereol. 2011;91(1):24-30.
4. Statistical Information Team, Cancer Research UK. United Kingdom Cancer Registry. Published 2012. http://www.cancerresearchuk.org. Accessed July 19, 2015.
5. Breitbart EW, Waldmann A, Nolte S, et al. Systematic skin cancer screening in Northern Germany. J Am Acad Dermatol. 2012;66(2):201-211.
6. Katalinic A, Waldmann A, Weinstock MA, et al. Does skin cancer screening save lives? an observational study comparing trends in melanoma mortality in regions with and without screening. Cancer. 2012;118(21):5395-5402.
7. Tinghög G, Carlsson P, Synnerstad I, Rosdahl I. Societal cost of skin cancer in Sweden in 2005. Acta Derm Venereol. 2008;88(5):467-473.
8. Stang A, Stausberg J, Boedeker W, Kerek-Bodden H, Jöckel KH. Nationwide hospitalization costs of skin melanoma and non-melanoma skin cancer in Germany. J Eur Acad Dermatol Venereol. 2008;22(1):65-72.
9. Vallejo-Torres L, Morris S, Kinge JM, Poirier V, Verne J. Measuring current and future cost of skin cancer in England. J Public Health (Oxf). 2014;36(1): 140-148.
10. Bigby M. Why the evidence for skin cancer screening is insufficient: lessons from prostate cancer screening. Arch Dermatol. 2010;146(3):322-324.
11. Gordon LG, Rowell D. Health system costs of skin cancer and cost-effectiveness of skin cancer prevention and screening: a systematic review. Eur J Cancer Prev. 2015;24(2):141-149. Medline
12. Waldmann A, Nolte S, Weinstock MA, et al. Skin cancer screening participation and impact on melanoma incidence in Germany: an observational study on incidence trends in regions with and without population-based screening. Br J Cancer. 2012;106(5):970-974.
13. Osborne JE. Skin cancer screening and surveillance. Br J Dermatol. 2002;146(5):745-754.
14. Girgis A, Clarke P, Burton RC, Sanson-Fisher RW. Screening for melanoma by primary health care physicians: a cost-effectiveness analysis. J Med Screen. 1996;3(1):47-53.
15. Losina E, Walensky RP, Geller A, et al. Visual screening for malignant melanoma: a cost-effectiveness analysis. Arch Dermatol. 2007; 143(1):21-28.
16. Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol. 2002;3(3):159-165.
17. Vestergaard ME, Macaskill P, Holt PE, Menzies SW. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. Br J Dermatol. 2008;159(3):669-676.
18. Peppercorn J, Zafar SY, Houck K, Ubel P, Meropol NJ. Does comparative effectiveness research promote rationing of cancer care? Lancet Oncol. 2014;15(3):e132-e138. doi:10.1016/S1470-2045(13)70597-7.
19. Korfage IJ, Essink-Bot ML, Westenberg SM, Helmerhorst T, Habbema JD, van Ballegooijen M. How distressing is referral to colposcopy in cervical cancer screening? a prospective quality of life study. Gynecol Oncol. 2014;132(1):142-148.
20. Keyzer-Dekker CM, De Vries J, van Esch L, et al. Anxiety after an abnormal screening mammogram is a serious problem. Breast. 2012;21(1):83-88.
21. Facco E, Zanette G, Favero L, et al. Toward the validation of Visual Analogue Scale for Anxiety. Anesth Prog. 2011;58(1):8-13.
22. Kindler CH, Harms C, Amsler F, Ihde-Scholl T, Scheidegger D. The visual analog scale allows effective measurement of preoperative anxiety and detection of patients' anesthetic concerns. Anesth Analg. 2000;90(3):706-712.
23. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol. 1988;124(6):869-871.
24. Garbe C, Büttner P, Weiss J, et al. Associated factors in the prevalence of more than 50 common melanocytic nevi, atypical melanocytic nevi, and actinic lentigines: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. J Invest Dermatol. 1994;102(5):700-705.
25. Garbe C, Büttner P, Weiss J, et al. Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. J Invest Dermatol. 1994;102(5):695-699.
26. Waldmann A, Nolte S, Geller AC, et al. Frequency of excisions and yields of malignant skin tumors in a population-based screening intervention of 360, 288 whole-body examinations. Arch Dermatol. 2012;148(8):903-910.
27. van der Leest RJ, de Vries E, Bulliard JL, et al. The Euromelanoma skin cancer prevention campaign in Europe: characteristics and results of 2009 and 2010. J Eur Acad Dermatol Venereol. 2011;25(12):1455-1465.
28. Bulliard JL, Maspoli M, Panizzon RG, Hohl D, Gueissaz F, Levi F. Evaluation of the Euromelanoma skin cancer screening campaign: the Swiss experience. J Eur Acad Dermatol Venereol. 2008;22 (3):365-366.
29. Stratigos A, Nikolaou V, Kedicoglou S, et al. Melanoma/skin cancer screening in a Mediterranean country: results of the Euromelanoma Screening Day Campaign in Greece. J Eur Acad Dermatol Venereol. 2007;21(1):56-62.
30. Argenziano G, Zalaudek I, Hofmann-Wellenhof R, et al. Total body skin examination for skin cancer screening in patients with focused symptoms. J Am Acad Dermatol. 2012;66(2):212-219.
31. Kiiski V, de Vries E, Flohil SC, et al. Risk factors for single and multiple basal cell carcinomas. Arch Dermatol. 2010;146(8):848-855.
32. Anders MP, Nolte S, Waldmann A, et al. The German SCREEN project: design and evaluation of the communication strategy. Eur J Public Health. 2014.
33. Kristensson JH, Sander BB, von Euler-Chelpin M, Lynge E. Predictors of non-participation in cervical screening in Denmark. Cancer Epidemiol. 2014;38(2):174-180.
34. von Euler-Chelpin M, Olsen AH, Njor S, et al. Does educational level determine screening participation? Eur J Cancer Prev. 2008;17(3):273-278.
35. Rogers HW, Coldiron BM. A relative value unit-based cost comparison of treatment modalities for nonmelanoma skin cancer: effect of the loss of the Mohs multiple surgery reduction exemption. J Am Acad Dermatol. 2009;61(1):96-103.
36. Millar K, Jelicic M, Bonke B, Asbury AJ. Assessment of preoperative anxiety: comparison of measures in patients awaiting surgery for breast cancer. Br J Anaesth. 1995;74(2):180-183.